**The April 2026 Department of Justice order, following President Trump’s December 2025 executive order, immediately moved FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III under the Controlled Substances Act, effective April 28.** This partial rescheduling addressed a portion of the 2024 proposed rulemaking while launching an expedited administrative hearing on broader rescheduling of all marijuana to Schedule III. The hearing, which began June 29, 2026, and was scheduled to conclude by mid-July, allows the DEA to receive evidence and expert input before any final rule. Trader sentiment reflects the completed medical pathway alongside uncertainty over the timeline and outcome of the remaining rulemaking, potential appeals, and whether further executive or legislative steps accelerate or delay full rescheduling.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$784,600 Vol.
September 30
14%
December 31
20%
$784,600 Vol.
September 30
14%
December 31
20%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Market Opened: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...**The April 2026 Department of Justice order, following President Trump’s December 2025 executive order, immediately moved FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III under the Controlled Substances Act, effective April 28.** This partial rescheduling addressed a portion of the 2024 proposed rulemaking while launching an expedited administrative hearing on broader rescheduling of all marijuana to Schedule III. The hearing, which began June 29, 2026, and was scheduled to conclude by mid-July, allows the DEA to receive evidence and expert input before any final rule. Trader sentiment reflects the completed medical pathway alongside uncertainty over the timeline and outcome of the remaining rulemaking, potential appeals, and whether further executive or legislative steps accelerate or delay full rescheduling.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions